for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pacira Biosciences Inc

PCRX.OQ

Latest Trade

59.29USD

Change

0.38(+0.65%)

Volume

107,848

Today's Range

57.67

 - 

59.40

52 Week Range

48.23

 - 

80.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
58.91
Open
58.75
Volume
107,848
3M AVG Volume
8.94
Today's High
59.40
Today's Low
57.67
52 Week High
80.00
52 Week Low
48.23
Shares Out (MIL)
44.03
Market Cap (MIL)
2,584.29
Forward P/E
19.58
Dividend (Yield %)
--

Next Event

Q2 2021 Pacira Biosciences Inc Earnings Release

Latest Developments

More

Pacira Announces Exparel Distribution Agreement With Eurofarma In Latin America

Pacira Biosciences Reports Preliminary Net Product Sales Of $42.2 Million For May 2021

Pacira Biosciences Announces Top-Line Results From Phase 3 Stride Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pacira Biosciences Inc

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry

Biotechnology & Drugs

Contact Info

5 Sylvan Way Ste 300

PARSIPPANY, NJ

07054-3813

United States

+1.973.2543560

http://www.pacira.com/

Executive Leadership

David M. Stack

Chairman of the Board, Chief Executive Officer

Charles A. Reinhart

Chief Financial Officer

Max Reinhardt

President - Rest of World

Kristen Williams

Chief Administrative Officer, Secretary

Charles Laranjeira

Chief Technical Officer

Key Stats

2.00 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.3K

2019

0.4K

2020

0.4K

2021(E)

0.5K
EPS (USD)

2018

1.040

2019

1.670

2020

2.210

2021(E)

2.985
Price To Earnings (TTM)
17.70
Price To Sales (TTM)
5.83
Price To Book (MRQ)
3.96
Price To Cash Flow (TTM)
15.40
Total Debt To Equity (MRQ)
72.06
LT Debt To Equity (MRQ)
48.76
Return on Investment (TTM)
16.45
Return on Equity (TTM)
14.01

Latest News

Latest News

BRIEF-Pacira Biosciences Announces Pricing Of $350 Mln Aggregate Principal Amount Of 0.750% Convertible Senior Notes Due 2025

* PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $350.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.750% CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

BRIEF-Pacira Biosciences Announces Proposed Offering Of $300.0 Mln Aggregate Principal Amount Of Convertible Senior Notes

* PACIRA BIOSCIENCES, INC. ANNOUNCES PROPOSED OFFERING OF $300.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES

BRIEF-Pacira Biosciences Reports Q2 Revenue Of $75.5 Mln Vs $102.6 Mln

* PACIRA BIOSCIENCES REPORTS PRELIMINARY TOTAL REVENUE OF $75.5 MILLION FOR SECOND QUARTER OF 2020

BRIEF-Pacira Biosciences Reports Q1 2020 Financial Results

* PACIRA BIOSCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Pacira Biosciences Appoints Donald C. Manning As Chief Medical Officer

* PACIRA BIOSCIENCES APPOINTS DONALD C. MANNING, M.D., PH.D. AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Pacira Reports Q4 Loss Per Share Of $0.12

* PACIRA REPORTS RECORD FOURTH QUARTER AND FULL-YEAR REVENUES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up